Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Clarithromycin · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Clarithromycin 250 mg immediate-release oral tablet |
| 2 | ACTIVE_COMPARATOR | Biaxin® (Clarithromycin) 250 mg tablet |
| Name | Type | Description |
|---|---|---|
| Clarithromycin | PROCEDURE | Single-dose of Clarithromycin 250 mg oral immediate-release tablets |
Inclusion Criteria: Subjects meeting all of the following criteria may be included in the study: Availability of volunteer for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form (ICF) duly signed by the volunteer Males or females a...
Clarithromycin is a small molecule drug developed by Viatris Inc. (ticker VTRS). It has been studied in Phase 1 clinical trials, and the specific therapeutic indication for these studies is undisclosed. The trials to date have focused on comparative bioavailability in healthy adult volunteers.
Clarithromycin is developed by Viatris Inc., which trades under the ticker VTRS. Viatris is the sponsor associated with the clinical development program for this small molecule asset.
Clarithromycin is in Phase 1 clinical development. All three of its recorded trials are Phase 1 studies, and all three have been completed. There are currently no active trials listed for this asset.
Clarithromycin has been evaluated in three completed Phase 1 trials: NCT00648960, a bioavailability study of 500 mg tablets in the fasting state; NCT00648830, a bioavailability study of 250 mg tablets; and NCT00648128, a bioavailability study of 500 mg tablets in the fed state. All enrolled healthy volunteers in Canada.
The three completed Phase 1 trials of Clarithromycin enrolled a total of 140 healthy volunteers. NCT00648960 enrolled 64 participants, NCT00648128 enrolled 44, and NCT00648830 enrolled 32. All trials were randomized and active controlled, and participants were 18 years or older.